OKT3 rescue for steroid-resistant rejection in adult liver transplantation.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Transplantation

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00007890-199301000-00017PMID 8420070
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• LYMPHOPROLIFERATIVE DISORDER MASQUERADING AS REJECTION IN LIVER TRANSPLANT RECIPIENTS‐AN EARLY AGGRESSIVE TUMOR WITH TYPICAL PRESENTATION

  1992cited by this paper
• Is sequential use of ALG and OKT3 in renal transplants associated with an increased incidence of fulminant posttransplant lymphoproliferative disorder?

  1991cited by this paper
• OKT3 THERAPY FOR HEPATIC ALLOGRAFT REJECTION: DIFFERENTIAL RESPONSE IN ADULTS AND CHILDREN

  1991cited by this paper
• Severe ductopenic rejection with features of vanishing bile duct syndrome: clinical, biochemical, and histologic evidence for spontaneous resolution.

  1991cited by this paper
• The surgical implications of the posttransplant lymphoproliferative disorders.

  1991cited by this paper
• Relationship between OKT3 administration, EBV seroconversion, and the lymphoproliferative syndrome in pediatric liver transplant recipients.

  1991cited by this paper
• THE LONG‐TERM OUTCOME OF OKT3 COMPARED WITH CYCLOSPORINE PROPHYLAXIS AFTER LIVER TRANSPLANTATION

  1991cited by this paper
• Acute pulmonary insufficiency due to OKT3 therapy.

  1990cited by this paper
• A randomized clinical trial of prophylactic OKT3 monoclonal antibody in liver allograft recipients.

  1990cited by this paper
• Prolonged and repeated courses of OKT3 after liver transplantation.

  1990cited by this paper
• Infection in OKT3-treated patients receiving additional antirejection therapy.

  1989cited by this paper
• Rejection in liver transplantation

  1989cited by this paper
• Lymphocyte parameters in liver graft recipients receiving prophylactic OKT3 or conventional triple therapy.

  1989cited by this paper
• Randomized prospective trial of OKT3 for early prophylaxis of rejection after liver transplantation.

  1989cited by this paper
• Liver transplantation in the Cambridge/King's College Hospital series--the first 400 patients.

  1989cited by this paper
• Experience with Orthoclone OKT3 monoclonal antibody in liver transplantation.

  1988cited by this paper
• The use of OKT3 rescue therapy after orthotopic liver transplantation--the University of Nebraska Medical Center experience.

  1988cited by this paper
• The diagnosis and treatment of posttransplant lymphoproliferative disorders.

  1988cited by this paper
• Infection and rejection of primary hepatic transplant in 93 consecutive patients treated with triple immunosuppressive therapy.

  1988cited by this paper
• Infectious complications in liver transplantation.

  1988cited by this paper
• A prospective study on the use of monoclonal anti-T3-cell antibody (OKT3) to treat steroid-resistant liver transplant rejection.

  1987cited by this paper
• OKT3 in the reversal of acute hepatic allograft rejection.

  1987cited by this paper
• Orthoclone OKT3 monoclonal antibody reversal of hepatic and cardiac allograft rejection unresponsive to conventional immunosuppressive treatments.

  1987cited by this paper
• Adult liver transplantation: An analysis of the early causes of death in 40 consecutive cases

  1986cited by this paper

• Immunosuppression Post-Liver Transplant: End of the Calcineurin Era?

  2025cites this paper
• Immunosuppressive Drugs in Liver Transplant: An Insight.

  2022cites this paper
• Antibody Drug Treatment for Steroid-Resistant Rejection After Pediatric Living Donor Liver Transplantation: A Single-Center Experience.

  2018cites this paper
• Immunomodulatory Activity of Ethanolic Extract of Propolis (Apismellifera Linn) on Cyclophosphamide Treated Immunosuppressed Rats

  2017cites this paper
• Immunology of Liver Transplantation

  2016cites this paper
• Immunosuppressive Biologic Agents

  2015cites this paper
• Current status of immunosuppression in liver transplantation.

  2013cites this paper
• [Basiliximab in the treatment of acute steroid-resistant rejection after liver transplantation].

  2012cites this paper
• Anti‐lymphocyte therapy successfully controls late “cholestatic” rejection in pediatric liver transplant recipients

  2011cites this paper
• The immunoreactive patient: Rejection and autoimmune disease

  2011cites this paper
• Muromonab-CD3 for the successful treatment of early chronic rejection after pediatric liver transplantation: Report of a case

  2011cites this paper
• Antibody immunosuppressive therapy in solid organ transplant

  2010cites this paper
• Liver transplant: a primer.

  2010cites this paper
• Muromonab-CD3 therapy for refractory rejections after liver transplantation: a single-center experience during two decades in Japan

  2010cites this paper
• Antibody immunosuppressive therapy in solid-organ transplant: Part I.

  2010cites this paper
• Antibody immunosuppressive therapy in solid-organ transplant

  2010cites this paper
• Anti‐CD3 mAbs for treatment of type 1 diabetes

  2009cites this paper
• Overview of immunosuppression in liver transplantation.

  2009cites this paper
• Steroid-resistant late acute rejection after a living donor liver transplantation: case report and review of the literature.

  2007cites this paper
• Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy.

  2005cites this paper
• Treatment of steroid-resistant acute liver transplant rejection with basiliximab.

  2005cites this paper
• Induction and Maintenance of Immunosuppression

  2005cites this paper
• The willingness of patients to accept an additional mortality risk in order to improve renal graft survival.

  2004cites this paper
• Therapy for Acute Rejection in Pediatric Organ Transplant Recipients

  2003cites this paper
• Mechanisms of Pharmacologic Immune Suppression

  2003cites this paper
• Acute cellular rejection in liver transplant recipients under cyclosporine immunosuppression: predictive factors of response to antirejection therapy

  2002cites this paper
• Correlação do esquema de imunossupressão com complicações pós-operatórias em transplantes renais através do uso da cintilografia renal dinâmica

  2001cites this paper
• Anti‐CD3 Induced Thymocyte Apoptosis In Vivo Require the Antibody Fc Domain

  2000cites this paper
• Grundvallaratriði í meðferð líffæraþega

  2000cites this paper
• Immunosuppressive agents in organ transplantation: past, present, and future.

  2000cites this paper
• Modern immunosuppression.

  2000cites this paper
• Immunologic Aspects of Transplant Management: Pharmacotherapy and Rejection

  2000cites this paper
• Advances in liver transplantation: overview and status.

  1999cites this paper
• Part IV. Advances in liver transplantation: Overview and status

  1999cites this paper
• Cytomegalovirus disease is associated with increased cost and hospital length of stay among orthotopic liver transplant recipients.

  1997cites this paper
• A randomized clinical trial of ursodeoxycholic acid as adjuvant treatment to prevent liver transplant rejection

  1997cites this paper
• Incidence, risk factors, and outcome of antithymocyte globulin treatment of steroid-resistant rejection after liver transplantation

  1996cites this paper
• Prognostic value of eosinophils for therapeutic response in severe acute hepatic allograft rejection.

  1996cites this paper
• Enhanced risk of steroid-resistant acute rejection following pretransplant steroid therapy in liver graft recipients.

  1995cites this paper
• Acute cellular rejection after liver transplantation: variability, morbidity, and mortality.

  1995cites this paper
• Currrent and future application of monoclonal antibodies in clinical immunosuppressive protocols

  1995cites this paper
• The Treatment of Intractable Rejection with Tacrolimus (FK506) in Pediatric Liver Transplant Recipients

  1995cites this paper
• FK 506 rescue therapy for intractable liver allograft rejection

  1994cites this paper
• Immunosuppressive agents.

  1994cites this paper
• Advances in diagnosis, prevention, and management of hepatic allograft rejection.

  1994cites this paper
• OKT3 monoclonal antibody treatment of steroid-resistant liver transplant rejection

  1994cites this paper
• Outcomes of rejection in adult liver transplant recipients--the Queensland experience.

  1993cites this paper
• Rejection: FK 506 for rescue or maintenance.

  1993cites this paper